COMPOUND PROFILE / SMALL MOLECULES
Lotiglipron.
Research draftLotiglipron is an oral small-molecule GLP-1 receptor agonist whose development was stopped.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Lotiglipron is an oral small-molecule GLP-1 receptor agonist whose development was stopped.
Mechanism
It activates GLP-1 signalling through a non-peptide structure.
Human research
Phase 1 and phase 2 studies measured metabolic responses, but the programme encountered safety and exposure concerns.
Preclinical & other research
Receptor studies informed development.
Safety & unknowns
Elevated liver enzymes and pharmacokinetic findings contributed to discontinuation.
Regulatory status
Discontinued investigational programme; it should not be presented as an available approved therapy.
Reported use & evidence
The supplied Lotiglipron profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.